3SBio Pays $100 Million To Market Two AstraZeneca PLC Diabetes Drugs In China

3SBio paid $100 million for exclusive rights to market two AstraZeneca diabetes products in China. The two products, Byetta and Bydureon, are injectable Glucagon-Like Peptide-1 antagonists intended for type 2 diabetes patients. Byetta is dosed twice-daily while Bydureon is administered once per week. 3SBio will pay $50 million upfront and $25 million when China issues import licenses for the Bydureon single dose tray and again for the Bydureon dual chamber pen. Previously, 3SBio was not involved in the diabetes market.

Back to news